September 13, 2016 — Lawsuits have been filed by more than 50 women who suffered permanent hair loss after using Taxotere in their breast cancer chemotherapy treatment.
Lawyers for two women who filed lawsuits in California say the lawsuits are spread out in 27 federal courts nationwide.
On September 7, they filed a response (PDF) in support of centralizing the cases in the Northern District of California:
“Thousands more cases will likely be filed in this matter, due to the widespread use of the drug and the significant percentage of women impacted by permanent hair loss.”
A panel of federal judges will meet on September 29 to decide whether to create a Multi-District Litigation (MDL) to centralize Taxotere lawsuits in one federal court.
Sanofi-Aventis is accused of failing to provide adequate warnings about permanent baldness to patients and doctors in the United States. Lawyers say the drug-maker knew or should have known about the risk.
The FDA ordered label updates in December 2015, nearly a decade after warnings about permanent alopecia were issued in Europe. Labels were updated in Canada in 2012.
In 2005, clinical trials of breast cancer patients who were treated with Taxotere, Adriamycin, and Cyclophosphamide (TAC regimen) found that 10% of patients had hair loss that persisted for up to 10 years and 5 months, and in some cases longer.
Do I have a Taxotere Lawsuit?
The Schmidt Firm, PLLC is currently accepting Taxotere induced injury cases in all 50 states. If you or somebody you know has been diagnosed with permanent baldness, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.
Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.